The Scientific Journey Behind Ozempic (with Lotte Bjerre Knudsen, Novo Nordisk's Chief Scientific Advisor)

ACQ2 by Acquired

Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Ben Gilbert and David Rosenthal, Ben Gilbert, and David Rosenthal 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

8M ago 1:00:05

MP3•에피소드 홈

On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:

The science behind what is happening in the body that causes weight loss while on Ozempic
What it was like in the 1990s and 2000s believing in a drug for a problem that the rest of the industry (including her own company) had written off
How weight loss was actually a goal from the very start — not just a side effect of diabetes medication like you often read today!

Sponsors:

Vanta

103 에피소드

#Ben Gilbert and David Rosenthal #Ben Gilbert #David Rosenthal #Trading #Entrepreneur #Business #Ben And Davids